...
首页> 外文期刊>Leukemia and lymphoma >The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma.
【24h】

The prognostic value of the expression of Bcl-2, p53 and LMP-1 in patients with Hodgkin's lymphoma.

机译:Bcl-2,p53和LMP-1表达在霍奇金淋巴瘤患者中的预后价值。

获取原文
获取原文并翻译 | 示例

摘要

This study was undertaken to evaluate the clinical significance of the expression of Bcl-2, p53 and LMP-1 in Hodgkin and Reed - Sternberg cells of patients with Hodgkin's lymphoma. The expression of these proteins in pre-treatment tissue biopsy specimens was correlated with presenting clinical features, failure-free survival (FFS) and overall survival (OS) in 83 patients with a confirmed Hodgkin's lymphoma treated in a single institution. HIV-positive patients were excluded. Patients were classified according to the International Prognostic Score (IPS) in low-risk (0 - 2 factors) and high-risk groups. The median age was 41 years (15 - 84), 41% were women, and 93% had advanced-stage disease (IIB - IVB). The expression of Bcl-2, p53 and LMP-1 was not associated with the complete remission rate, FFS or OS. The IPS risk group was the only factor significantly associated with OS. Patients with a high IPS had a lower 5 year OS (43% vs. 79%, P = 0.003). The expression of Bcl-2, p53 and LMP-1 did not add prognostic information to the IPS.
机译:这项研究旨在评估霍奇金淋巴瘤患者的霍奇金和里德-斯特恩伯格细胞中Bcl-2,p53和LMP-1表达的临床意义。这些蛋白质在治疗前组织活检标本中的表达与单一机构接受确诊霍奇金淋巴瘤的83例患者的临床特征,无失败生存率(FFS)和总体生存率(OS)相关。 HIV阳性患者被排除在外。根据国际预后评分(IPS)将患者分为低风险(0-2个因素)和高风险组。中位年龄为41岁(15-84岁),女性占41%,晚期疾病(IIB-IVB)为93%。 Bcl-2,p53和LMP-1的表达与完全缓解率,FFS或OS无关。 IPS风险组是与操作系统显着相关的唯一因素。 IPS高的患者的5年OS较低(43%比79%,P = 0.003)。 Bcl-2,p53和LMP-1的表达未向IPS增加预后信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号